Argos Therapeutics Inc

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The company’s most advanced product candidate is AGS-003, which it is developing for the treatment of metastatic renal cell carcinoma, or mRCC, and other cancers.

Argos is currently enrolling patients in a pivotal phase 3 clinical trial of AGS-003 in combination with sunitinib (Sutent) for the treatment of mRCC under a special protocol assessment, or SPA, with the Food and Drug Administration, or FDA. The primary endpoint of the phase 3 clinical trial is overall survival. In the phase 2 clinical trial of AGS-003 in combination with sunitinib in mRCC patients, median overall survival was 30.2 months. This compares to median overall survival of 14.7 months in 1,189 mRCC patients with similar risk factors who were treated with sunitinib or other targeted therapies as shown in data collected by the International Metastatic Renal Cell Carcinoma Database Consortium, or the Consortium.

The company is developing its second Arcelis product candidate, AGS-004, for the treatment of HIV and are conducting a phase 2b clinical trial of AGS-004 that is being funded entirely by the National Institutes of Health, or NIH, under a $39.3 million contract.

Argos Therapeutics was incorporated under the laws of the State of Delaware in 1997 under the name Dendritix, Inc. It changed its name to Merix Bioscience, Inc. in 1999, and to Argos Therapeutics, Inc. in 2004. Its website address is www.argostherapeutics.com.